THURSDAY, FEBRUARY 23, 2023
Generic prescription drugs can offer cost savings up to 85% from brand name medication, and now many brand named patented drugs will become available in generic forms.
|
January
|
Humira (adalimumab),Ibrance (palbociclib), Nascobal (cyanocobalamin intranasal), Teflaro (ceftaroline), Trokendi XR (topiramate).
|
|
February
|
Latuda (lurasidone), Vyvanse (Lisdexamfetamine)
|
|
March
|
Aggrastat (tirofiban), Aubagio (teriflunomide), Gattex (teduglutide)
|
|
April
|
Corlanor (Ivabradine), Edurant (rilpivirine)
|
|
May
|
Livalo (pitavastatin)
|
|
July
|
Mozobil (plerixafor), Qtern (dapagliflozin/saxagliptin)
|
|
December
|
Victoza (liraglutide)
|
|
Later in 2023
|
Iressa (gefitinib), Lexiscan (regadenoson), Lucentis (ranibizumab), Myrbetriq(mirabegron), Onglyza (saxagliptin), Prezista (darunavir), Prolensa (bromfenac 0.07%), Treanda (bendamustine HCl)
|
Posted 5:52 PM
No Comments
Post a Comment |
|
Required
|
|
Required (Not Displayed)
|
|
Required
|
All comments are moderated and stripped of HTML.
|
|
|
|
|
|
NOTICE: This blog and website are made available by the publisher for educational and informational purposes only.
It is not be used as a substitute for competent insurance, legal, or tax advice from a licensed professional
in your state. By using this blog site you understand that there is no broker client relationship between
you and the blog and website publisher.
|
Blog Archive
|
|